bioAffinity Technologies Inc

BIAF

2.170USD

+0.080+3.83%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

bioAffinity Technologies Inc's Score

Industry at a Glance

Industry Ranking

134 / 210

Overall Ranking

321 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

6.000

Target Price

+2190.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

bioAffinity Technologies Inc Highlights

StrengthsRisks

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 194820.30% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.36M.

Undervalued

The company’s latest PE is -3.11, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 130.40K shares, increasing 46.10% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.35K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.80.

The company's current financial score is 6.83, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.27M, representing a year-over-year decrease of 47.05%, while its net profit experienced a year-over-year decrease of 92.43%.

Score

Industry at a Glance

Previous score

6.83

Change

0



Financials

4.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.39

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.39, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -3.11, which is -92.21% below the recent high of -0.24 and -143.78% above the recent low of -7.59.

Score

Industry at a Glance

Previous score

6.39

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 134/210

No Data

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for bioAffinity Technologies Inc is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.71, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 3.11 and the support level at 1.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

0.11

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 2.90%, representing a quarter-over-quarter decrease of 86.04%. The largest institutional shareholder is The Vanguard, holding a total of 1.35K shares, representing 0.03% of shares outstanding, with 98.20% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Crumly (Richard K)

60.25K

--

Bigger Capital Funds, LP

58.68K

--

District 2 Capital LP

58.68K

--

Girgenti (Steven)

36.30K

--

Rubin (Gary D)

22.31K

--

The Joyce Living Trust

19.44K

+3.55%

Zannes (Maria)

12.79K

+36.95%

Anderson (Robert A)

5.46K

--

Geode Capital Management, L.L.C.

4.18K

+5.71%

Edwards (James Michael CPA)

4.00K

--



1

2



The company’s current risk assessment score is 1.04, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

bioAffinity Technologies Inc

BIAF

5.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Castle Biosciences Inc

CSTL

8.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

TCMD

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Artivion Inc

AORT

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment